ProtoKinetix’ Advisory Boards Launch Major Commercial Initiatives for It’s AAGPs™
VANCOUVER-(Business Wire)-September 24, 2009 - ProtoKinetix’ Business Advisory Board Chairman, Rear Admiral (Ret) Dr. Edward Martin, reported on progress implemented by the Corporate Advisory Boards. Attending the recent conference were Major General (Ret) Dr. John Parker and Vice Admiral (Ret) Dr. Harold Koenig of the Scientific Advisory Board meeting with corporate management.
In addition to the several major corporations currently evaluating AAGP™, the Advisory Boards have been able to successfully present the ProtoKinetix family of anti-aging glycopeptides to several senior pharmaceutical executives. These initiatives are predominantly structured to build partnering/licensing relationships using AAGP™ in medical therapies and regenerative medicine.
Over the past three years AAGP™ has been tested as a novel molecular structure by numerous scientists in research laboratories, universities and corporations. “Medical researchers are now accepting the role of glycopeptides in therapeutic medicine and skin care. The Advisory Boards are looking forward to report on a frequent basis as these commercialization campaigns progress” says Dr. Martin.
About ProtoKinetix
ProtoKinetix, Inc. is a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides AAGP™ for medicine and the biotechnology and cosmetic industries. PKTX is currently in dialog with major corporations and institutions who have contacted the Company about the broad range of applications for AAGP™ products. For more detailed information, visit our website at: www.protokinetix.com
The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements. Some information included in this press release contains statements that are forward-looking. Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company. For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.
Ross L. Senior, LLB – President and CEO
Company Office
2225 Folkestone Way,
West Vancouver, B.C.,
604-926-6627
V7S 2X6
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
